References
- 1. C. Cernik, K. Gallina and R. T. Brodell, The treatment of herpes simplex infections: an evidence-based review, Arch. Intern. Med.168 (2008) 1137–1144; DOI: 10.1001/archinte.168.11.1137.
- 2. K. S. Erlich, Management of herpes simplex and varicella-zoster virus infections, West. J. Med.166 (1997) 211–215.
- 3. D. M. Thappa, Textbook of Dermatology, Leprology, and Venereology, 3rd ed., Elsevier, Gurgaon 2009, pp. 350–351.
- 4. J. Arnal, I. Gonzalez-Alvarez, M. Bermejo, G. L. Amidon, H. E. Junginger, S. Kopp, K. K. Midha, V. P. Shah, S. Stavchansky, J. B. Dressman and D. M. Barends, Biowaiver monographs for immediate release solid oral dosage forms: acyclovir, J. Pharm. Sci.97 (2008) 5061–5073; DOI: 10.1002/jps.21392.
- 5. R. Sankar and S. Jain, Approaches for enhancing the bioavailability of acyclovir: a critical review, Int. J. Pharm. Biol. Sci. 4 (2013) 623–633.
- 6. K. M. Lutker, R. Quinones, J. Xu, A. Ramamoorthy and A. J. Matzger, Polymorphs and hydrates of acyclovir, J. Pharm. Sci. 3 (2011) 949–963; DOI: 10.1002/jps.22336.
- 7. K. Terada, H. Kurobe, M. Ito, Y. Yoshihashi, E. Yonemochi, K. Fujii and H. Uekusa, Polymorphic transformation behavior of acyclovir based on the thermodynamics and crystallography, J. Therm. Anal. Calorim.113 (2013) 1261–1267; DOI: 10.1007/s10973-013-3140-1.
- 8. A. Kristl, S. Srcic, F. Vrecer, B. Sustar and D. Vojnovic, Polymorphism and pseudopolymorphism: influencing the dissolution properties of the guanine derivative acyclovir, Int. J. Pharm.139 (1996) 231–235; DOI: 10.1016/0378-5173(96)04601-7.
- 9. Y. T. Sohn and S. H. Kim, Polymorphism and pseudopolymorphism of acyclovir, Arch. Pharm. Res.31 (2008) 231–234; DOI: 10.1007/s12272-001-1146-x.
- 10. P. K. Ghosh, R. J. Majithiya, M. L. Umrethia and R. S. R. Murthy, Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability, AAPS PharmSciTech.7 (2006) 172–177; DOI: 10.1208/pt070377.
- 11. C. Von Plessing Rossel, J. S. Carreño, M. Rodríguez-Baeza and J. B. Alderete, Inclusion complex of the antiviral drug acyclovir with cyclodextrin in aqueous solution and in solid phase, Quimica Nova23 (2000) 749–752; DOI: 10.1590/S0100-40422000000600007.
- 12. T. Masuda, Y. Yoshihashi, E. Yonemochi, K. Fujii, H. Uekusa and K. Terada, Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir, Int. J. Pharm.422 (2012) 160–169; DOI: 10.1016/j.ijpharm.2011.10.046.
- 13. D. Patel and K. K. Sawant, Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS), Drug Dev. Ind. Pharm.33 (2007) 1318–1326; DOI: 10.1080/03639040701385527.
- 14. A. Kushwaha, S. K. Prajapati and B. Sharma, Comparative study of acyclovir solid dispersion for bioavailability enhancement, AJPTR1 (2011) 179–201.
- 15. R. Cortesi and E. Esposito, Acyclovir delivery systems, Expert Opin. Drug Deliv.5 (2008) 1217–1230; DOI: 10.1517/17425240802450340.
- 16. A. Kushwaha, Solid dispersion: an approach to enhance the dissolution rate of acyclovir, Int. J. Nov. Drug Deliv. Tech.2 (2012) 291–296.
- 17. N. Sachan, S. Pushkar, S. S. Solanki and D. S. Bhatere, Enhancement of solubility of acyclovir by solid dispersion and inclusion complexation methods, World Appl. Sci. J.11 (2010) 857–864.
- 18. B. Karolewicz, M. Gajda, A. Owczarek, J. Pluta and A. Górniak, Physicochemical and dissolution studies of simvastatin solid dispersions with Pluronic F127, Pharmazie69 (2014) 589–594; DOI: 10.1691/ph.2014.3217.
- 19. B. Karolewicz, A. Górniak, A. Owczarek, E. Żurawska-Płaksej, A. Piwowar and J. Pluta, Thermal, spectroscopic, and dissolution studies of ketoconazole–Pluronic F127 system, J. Therm. Anal. Calorim.115 (2014) 2487–2493; DOI: 10.1007/s10973-014-3661-2.
- 20. G. A. Shazly, M. A. Ibrahim, M. M. Badran and K. M. A. Zoheir, Utilizing Pluronic F-127 and Gelucire 50/13 solid dispersions for enhanced skin delivery of flufenamic acid, Drug Dev. Res.73 (2012) 299–307; DOI: 10.1002/ddr.21013.
- 21. P. Kumar, C. Mohan, M. K. S. U. Shankar and M. Gulati, Physiochemical characterization and release rate studies of solid dispersions of ketoconazole with Pluronic F127 and PVP K-30, Iran. J. Pharm. Res.10 (2011) 685–694.
- 22. N. Kolašinac, K. Kachrimanis, I. Homšek, B. Grujič, Z. Ðurič and S. Ibrič, Solubility enhancement of desloratadine by solid dispersion in poloxamers, Int. J. Pharm.15 (2012) 161–170; DOI: 10.1016/j.ijpharm.2012.06.060.
- 23. European Pharmacopoeia, 8th ed., European Directorate for the Quality of Medicines & Healthcare, Strasbourg 2014, pp. 331–333.
- 24. D. Q. M. Craig, The mechanisms of drug release from solid dispersions in water-soluble polymers, Int. J. Pharm.231 (2002) 131–144; DOI: 10.1016/S0378-5173(01)00891-2.
- 25. T. L. Threlfall, Analysis of organic polymorphs. A review, Analyst120 (1995) 2435–2460; DOI: 10.1039/AN9952002435.
- 26. M. G. Issa and H. G. Ferraz, Intrinsic dissolution as a tool for evaluating drug solubility in accordance with the Biopharmaceutics Classification System, Dissol. Technol.18 (2011) 6–13; DOI: 10.14227/DT180311P6.
- 27. L. X. Yu, A. S. Carlin, G. L. Amidon and A. S. Hussain, Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs, Int. J. Pharm.270 (2004) 221–227; DOI: 10.1016/j.ijpharm.2003.10.016.
- 28. L. X. Yu, G. L. Amidon, J. E. Polli, H. Zhao, M. U. Mehta, D. P. Conner, V. P. Shah, L. J. Lesko, M. Chen, V. H. L. Lee and A. S. Hussain, Biopharmaceutics classification system: The scientific basis for biowaiver extensions, Pharm. Res.19 (2002) 921–925; DOI: 10.1023/A:1016473601633.
- 29. P. Zakeri-Milani, M. Barzegar-Jalali, M. Azimi and H. Valizadeh, Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability, Eur. J. Pharm. Biopharm. 73 (2009) 102–106; DOI: 10.1016/j.ejpb.2009.04.015.
- 30. M. El-Badry, M. A. Hassan, M. A. Ibrahim and H. Elsaghir, Performance of Poloxamer 407 as hydrophilic carrier on the binary mixtures with nimesulide, Farmacia61 (2013) 1137–1150.